3 terminated, 1 completed, 1 recruiting. 3 Phase 4, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Terminated 2, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Daptomycin for Injection: new trials by email Literature Review of Daptomycin for Injection trials Research Report on Daptomycin for Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia Daptomycin for Injection, Vancomycin (IV) - Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia | Phase 4 | Recruiting | Todd C. Lee MD MPH FIDSA | 300 | 2024-11-14 | 2026-09-09 |
| Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029) Daptomycin for Injection - Bacteremia, Soft Tissue Infections | Phase 2 | Completed | Merck Sharp & Dohme LLC | 18 | 2018-12-06 | 2022-05-13 |
| Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE) daptomycin, daptomycin and gentamicin - Infective Endocarditis | Phase 4 | Terminated | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 24 | 2009-02-13 | 2021-02-02 |
| Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia daptomycin, vancomycin - Endocarditis, Bacterial, Infective Endocarditis | Phase 2 | Terminated | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 38 | 2008-09-17 | 2018-12-24 |
| Cubicin(R) for Complicated Post-surgical Wound Infections daptomycin - Wound Infections | Phase 4 | Terminated | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 69 | 2004-06-01 | 2017-08-30 |
Bacteremia (3) · Endocarditis (2) · Gram-Positive Bacterial Infections (2) · Staphylococcal Infections (2) · Endocarditis, Bacterial (1) · Infections (1) · Skin Diseases, Infectious (1) · Soft Tissue Infections (1) · Wound Infection (1)
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3) · Merck Sharp & Dohme LLC (1) · Todd C. Lee MD MPH FIDSA (1)
United States (2) · Australia (1) · Canada (1) · Japan (1) · New Zealand (1)
Paula Bokesch, M.D. (1) · Peter Pertel, MD (1) · Todd C Lee, MD MPH FIDSA (1)
2025 (1)